Survey
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
* Your assessment is very important for improving the workof artificial intelligence, which forms the content of this project
BIOPHARMACEUTICS & DRUG DISPOSITION Biopharm. Drug Dispos. (2014) Published online in Wiley Online Library (wileyonlinelibrary.com) DOI: 10.1002/bdd.1889 Nonclinical pharmacokinetics and metabolism of EPZ-5676, a novel DOT1L histone methyltransferase inhibitor Aravind Basavapathruni, Edward J. Olhava, Scott R. Daigle, Carly A. Therkelsen, Lei Jin, P. Ann Boriack-Sjodin, Christina J. Allain, Christine R. Klaus, Alejandra Raimondi, Margaret Porter Scott, Angelos Dovletoglou, Victoria M. Richon†, Roy M. Pollock, Robert A. Copeland, Mikel P. Moyer, Richard Chesworth, Paul G. Pearson, and Nigel J. Waters* Epizyme Inc., 400 Technology Square, Cambridge, MA, USA ABSTRACT: (2R,3R,4S,5R)-2-(6-Amino-9H-purin-9-yl)-5-((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d] imidazol-2-yl)ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol (EPZ-5676) is a novel DOT1L histone methyltransferase inhibitor currently in clinical development for the treatment of MLL-rearranged leukemias. This report describes the preclinical pharmacokinetics and metabolism of EPZ-5676, an aminonucleoside analog with exquisite target potency and selectivity that has shown robust and durable tumor growth inhibition in preclinical models. The in vivo pharmacokinetics in mouse, rat and dog were characterized following i.v. and p.o. administration; EPZ-5676 had moderate to high clearance, low oral bioavailability with a steady-state volume of distribution 2–3 fold higher than total body water. EPZ-5676 showed biexponential kinetics following i.v. administration, giving rise to a terminal elimination half-life (t1/2) of 1.1, 3.7 and 13.6 h in mouse, rat and dog, respectively. The corresponding in vitro ADME parameters were also studied and utilized for in vitro–in vivo extrapolation purposes. There was good agreement between the microsomal clearance and the in vivo clearance implicating hepatic oxidative metabolism as the predominant elimination route in preclinical species. Furthermore, low renal clearance was observed in mouse, approximating to fu-corrected glomerular filtration rate (GFR) and thus passive glomerular filtration. The metabolic pathways across species were studied in liver microsomes in which EPZ5676 was metabolized to three monohydroxylated metabolites (M1, M3 and M5), one N-dealkylated product (M4) as well as an N-oxide (M6). Copyright © 2014 John Wiley & Sons, Ltd. Key words: MLL-rearranged leukemia; nonclinical pharmacokinetics; in vitro–in vivo extrapolation; metabolite identification Introduction Recent advances in the understanding of cancer incidence have implicated epigenetics and epigenetic targets as potential avenues for therapeutic *Correspondence to: Epizyme Inc., 400 Technology Square, 4th Floor, Cambridge, MA 02139, USA. E-mail: [email protected] † Present address: Sanofi, 270 Albany Street, Cambridge, MA, 02139, USA Copyright © 2014 John Wiley & Sons, Ltd. intervention. Epigenetic modifications that may play a hand in cancer development range from changes in chromatin remodeling, DNA methylation or post-translational modifications of histones [1]. One such histone modification is strongly tied to a specific form of leukemia, in which translocation of the mixed lineage leukemia (MLL) gene results in MLL-fusion proteins that can aberrantly associate with the histone methyltransferase DOT1L (disruptor of telomeric silencing-1 like), resulting in ectopic DOT1L-catalysed methylation Received 5 August 2013 Revised 27 November 2013 Accepted 31 December 2013 A. BASAVAPATHRUNI ET AL. of lysine 79 of histone H3 (H3K79) [2–8]. Aberrant H3K79 methylation serves to drive the expression of MLL target genes and an oncogenic phenotype. The strong causality between the H3K79 methylation mark and a cancer phenotype provides an opportunity for small molecule intervention of DOT1L catalytic activity. We have reported previously structure-guided medicinal chemistry efforts that yielded a potent DOT1L inhibitor, EPZ004777, demonstrating the first meaningful proof of concept in histone methyltransferase (HMT) inhibition [9,10]. Further expansion of our medicinal chemistry efforts generated the potent molecule EPZ-5676 ((2R,3R,4S,5R)-2-(6-amino-9H-purin-9-yl)-5((((1r,3S)-3-(2-(5-(tert-butyl)-1H-benzo[d]imidazol-2-yl) ethyl)cyclobutyl)(isopropyl)amino)methyl)tetrahydrofuran-3,4-diol), an aminonucleoside analog with improved inhibition versus DOT1L in in vitro biochemical and cellular assays [11]. EPZ-5676 inhibits DOT1L with a Ki of ≤ 80 pM and displays 37000-fold selectivity over a panel of other HMTs. The potency is further exemplified by treatment in a rat xenograft model of MLL-rearranged leukemia with EPZ-5676, in which continuous intravenous (i.v.) infusion of EPZ-5676 caused complete tumor regressions that were sustained beyond the compound infusion period with no significant weight loss or signs of toxicity [11]. This report describes the preclinical pharmacokinetics and metabolism of EPZ-5676, a novel DOT1L inhibitor and the first member of the novel HMTi class to enter clinical development as a potential therapeutic agent in MLL-rearranged leukemia. The objectives of this work were to characterize the pharmacokinetics following i.v. and p.o. administration in mouse, rat and dog, to assess the cross-species in vitro–in vivo correlation and to identify the primary metabolic and elimination pathways involved in the clearance of EPZ-5676. Understanding the pharmacokinetic properties along with the remarkable potency of EPZ-5676 both in vitro and in vivo promoted the development of this molecule for acute leukemias bearing MLL-rearrangements. EPZ-5676 is currently in Phase I evaluation and represents not only the first reported histone methyltransferase inhibitor to enter human clinical trials, but a further step towards understanding the link between epigenetic processes and the pathophysiology of cancer. Copyright © 2014 John Wiley & Sons, Ltd. Materials and Methods Chemicals and reagents EPZ-5676 was synthesized by Epizyme [11]. All other reagents were purchased from sources as described below. In vivo pharmacokinetics All animal studies were conducted as per approved IACUC protocols. Pharmacokinetic study in mouse. The pharmacokinetics of EPZ-5676 was evaluated in male CD1mice (28–29 g, male, n = 21, purchased from BK Laboratory Animal Co. Ltd) following i.v. bolus administration of doses of 5 mg/kg and oral administration at doses of 20 mg/kg. Oral gavage and i.v. tail vein injection doses were administered in a 10% ethanol and 90% saline vehicle. For i.v. administration, blood samples were taken (n = 3 per time-point; two time-points per mouse) at 0.05, 0.167, 0.5, 1, 2, 4, 6 and 24 h post-dose into pre-chilled K2-EDTA tubes. For p.o. dosing, blood samples were taken (n = 3 per time-point; two time-points per mouse) at 0.167, 0.5, 1, 2, 4 and 6 h post-dose into pre-chilled K2-EDTA tubes. Blood samples were put on wet ice and centrifuged at 4°C (2000 × g for 5 min) to obtain plasma within 15 min of sample collection. Plasma samples were stored at 20 °C prior to LC-MS/ MS analysis. CD-1 mice (n = 3) also received a single 5 mg/kg i.v. administration of EPZ-5676 followed by urine collection in metabolism cages for 240 min post-dose. The urine aliquots were pooled, the total volume recorded and stored frozen at 20 °C prior to LC-MS/MS analysis. Pharmacokinetic study in rat. The pharmacokinetics of EPZ-5676 was evaluated in male SpragueDawley rats (n = 3 per dose route, 245–265 g, purchased from SLAC Laboratory Animal Co. Ltd). For the i.v. bolus, 1 mg/kg doses prepared in 0.4% hydroxypropyl-beta-cyclodextrin (HPBCD) in saline were administered via foot dorsal vein injection. For p.o. administration, 10 mg/kg doses prepared in 10% ethanol: 5% Solutol HS15: 85% (5% of dextrose in water) were administered by oral gavage. Serial blood sampling was employed in each animal at each time-point, 0.05, 0.217, 0.5, 1, Biopharm. Drug Dispos. (2014) DOI: 10.1002/bdd NONCLINICAL PK AND METABOLISM OF EPZ-5676, A DOT1L INHIBITOR 2, 4, 8 and 24 h following i.v. administration and 0.25, 0.5, 1, 2, 4, 6, 8 and 24 h following p.o. administration, with 150 μl of blood collected via the tail vein into pre-chilled K2-EDTA tubes. Blood samples were put on wet ice and centrifuged at 4 °C (2000 × g for 5 min) to obtain plasma within 15 min of sample collection. Plasma samples were stored at 20 °C prior to LC-MS/MS analysis. Pharmacokinetic study in dog. The intravenous (i.v.) pharmacokinetics of EPZ-5676 was evaluated in beagle dogs (male, n = 3, 7.5–8 kg purchased from Beijing Marshall Biotechnology Co. Ltd) following a single i.v. administration at a dose of 1 mg/kg. The i.v. doses were administered by a single intravenous infusion over 1 min into the cephalic vein in a 10% ethanol and 90% saline vehicle. At designated time-points (pre-dose, 0.083, 0.25, 0.5, 1, 2, 4, 8 and 24 h post-dose), the animals were restrained manually, and approximately 0.5 ml blood per time point was collected from the noninjected cephalic vein into pre-chilled K2-EDTA tubes. Blood samples were put on wet ice and centrifuged at 4 °C (2000 × g for 5 min) to obtain plasma within 15 min of sample collection. Plasma samples were stored at 20 °C prior to LC-MS/ MS analysis. LC-MS/MS bioanalysis and pharmacokinetic data analysis EPZ-5676 was extracted from K2-EDTA plasma or urine by protein precipitation using an acetonitrile-containing internal standard (a structural analog of EPZ-5676 at a concentration of 5 ng/ml). Typically, samples were injected onto an LC-MS/ MS system using a Waters BEH phenyl column. The aqueous mobile phase was water with 0.1% NH4OH (A), and the organic mobile phase was acetonitrile with 0.1% NH4OH (B). The gradient was as follows: 37% B for the first 0.2 min, increased to 44% B from 0.2 to 0.6 min, maintained at 44% B for 0.5 min, and decreased to 37% B within 0.05 min. The injection volume was 2 μl, and the total run time was 1.5 min with a flow rate of 0.6 ml/min. The retention time of EPZ-5676 was 0.85 min. The ionization was conducted in the positive ion mode using the multiple reaction monitoring (MRM) transition [M + H]+ m/z 563.5 parent ion to m/z 326.3 daughter ion, incorporating Copyright © 2014 John Wiley & Sons, Ltd. a turbo-ionspray interface. Eight to ten calibration standards were prepared in blank plasma or urine of the relevant species providing a typical standard curve concentration range of 0.5–1000 ng/ml. Calibration curves were performed in duplicate in each analytical run together with low, mid and high concentration QCs in duplicate. All standard and QC measured concentrations fell within 85–115% of the nominal concentration. Pharmacokinetic parameters were calculated by noncompartmental methods using WinNonlin (version 5.3; Pharsight, St Louis, Missouri). Terminal t1/2 values were determined by regression of at least three data-points in the later phase of the time–concentration profile. The volume of distribution at steady state was calculated as below: VDss¼ Dose · AUMC0 inf ðAUC0 inf Þ2 Parameters are presented as mean ± SD where applicable. Parent excretion in urine was calculated as the % dose excreted = (urine concentration * urine volume)/dose, accounting for the sample pooling across three animals. The renal clearance, CLr, was calculated as the amount in urine to time t/AUC0-t. In vitro stability assays in liver microsomes and hepatocytes Liver microsomes (final protein concentration 0.5 mg/ml), 0.1 M phosphate buffer at pH 7.4 and EPZ-5676 (final concentration of 3 μM; final dimethylsulfoxide (DMSO) concentration of 0.25%) were pre-incubated at 37 °C prior to the addition of NADPH (final concentration of 1 mM) to initiate the reaction. The final incubation volume was 50 μl. Control incubations were included for each species where 0.1 M phosphate buffer pH 7.4 was added instead of NADPH (minus NADPH). Positive control compounds (diazepam and diphenhydramine for rodent, verapamil and dextromethorphan for human, testosterone in all species) were incubated in parallel to confirm microsomal activity. The intrinsic clearance values obtained were within the range of historical data. EPZ-5676 and controls were incubated for 0, 5, 15, 30 and 45 min. The control (minus NADPH) was incubated for 45 min only. The reactions were stopped by transferring Biopharm. Drug Dispos. (2014) DOI: 10.1002/bdd A. BASAVAPATHRUNI ET AL. 25 μl of incubate to 50 μl methanol at the appropriate time points. The incubation plates were centrifuged at 1640 × g for 20 min at 4 °C to aid protein precipitation. Human, Beagle dog, Sprague-Dawley rat and CD-1 mouse cryopreserved hepatocytes were obtained from XenoTech and stored at 150 °C until use. The hepatocytes were thawed and prepared according to the vendor’s instructions, pooled into Krebs Henseleit buffer (KHB, pH 7.4), and kept on ice prior to initiating the experiment. The hepatocyte suspensions were pre-incubated in a shaking water bath at 37 °C for 3 min, and then the reaction was initiated by the addition of EPZ-5676 into the hepatocyte suspensions (1.5 × 106 cells/ml) at a final concentration of 3 μM, and a DMSO content of 0.1%. The reaction mixture was incubated in a shaking water bath at 37 °C. Aliquots of the incubation solutions were sampled at 0, 15, 30, 60 and 120 min. The reaction was immediately terminated by the addition of three volumes of ice-cold acetonitrile containing 0.1% formic acid and internal standards. After centrifugation at 1640 × g for 10 min, the supernatants were transferred into HPLC vials, and the test compound was analysed by LC-MS/MS. Testosterone (20 μM) and 7-hydroxycoumarin (100 μM), were performed in parallel to confirm the enzyme activities of the hepatocytes used. The in vitro t1/2 values were determined by plotting the natural logarithm of the analyte/IS peak area ratios versus time, with the slope of the linear regression (k) converted to in vitro t1/2 values by in vitro t1/2 = 0.693/k. Experimental half-lives were transformed to the corresponding scaled intrinsic clearance values (in units of ml/min/kg) as below: CL int ¼ 0:693 mL incubation · · MPPGL · LWPBW in vitro t1=2 mg microsones CL int ¼ 0:693 mL incubation · · HPGL · LWPBW in vitro t1=2 millioncells where MPPGL is microsomal protein per gram liver, HPGL is hepatocellularity (million cells per gram liver) and LWPBW is grams liver per kg body weight. The scaled intrinsic clearance values were then subsequently scaled to predicted in vivo clearance values, using the well-stirred venous equilibration Copyright © 2014 John Wiley & Sons, Ltd. model as described previously [12–14] and as shown below; CLH ¼ QH CL int QH þ CL int CLH ¼ QH f up CL int QH þ f up CL int where QH is the blood flow, fup is the fraction unbound in plasma and CLint is the scaled intrinsic clearance. The appropriate species-specific scaling factors including MPPGL, HPGL, LWPBW and hepatic blood flows were used throughout [15–17]. Since the microsomal incubational binding of EPZ5676 was measured close to unity (Table 2), the two versions of the well-stirred model that were applied to the data are as shown above; (i) scaled CL with no correction for binding parameters and (ii) scaled CL with correction for fraction unbound in plasma (fup) only. These data are presented in Table 2. Plasma protein binding, blood partitioning and plasma stability assays Plasma protein binding was assessed by equilibrium dialysis, utilizing the HT-dialysis cell format with a cellulose semi permeable membrane (molecular weight cut-off of 5000 Da). Plasma was warmed to 37 °C and adjusted to pH 7.4 before use. Male Sprague-Dawley rat, male Beagle dog, male CD-1 mouse and mixed sex human plasma (Harlan Sera-Lab Ltd, Loughborough, UK) were used for the studies. A 5 μM test compound solution was prepared in isotonic phosphate buffer and rat, dog, mouse and human plasma (final DMSO concentration of 0.5%). The plasma-containing solution was introduced to one side of the membrane, and the plasma-free on the other. Incubations were performed for 16 h in duplicate in order to allow the compound to reach equilibrium. Mass balance and recovery were assessed post-incubation and were > 85% in all cases. Haloperidol was incubated in parallel as the control compound for each species. At the end of the equilibration time the cells were emptied. Following protein precipitation, the samples were centrifuged and analysed by LC-MS/MS. The samples from the protein-containing compartment were quantified using calibration standards prepared in plasma and the protein-free compartments were quantified using calibration standards prepared in dialysis buffer. Using a similar methodology, the incubational binding of 3 μM EPZ-5676 to liver microsomes Biopharm. Drug Dispos. (2014) DOI: 10.1002/bdd NONCLINICAL PK AND METABOLISM OF EPZ-5676, A DOT1L INHIBITOR (0.5 mg/ml) from mouse, rat, dog and human was assessed, with amitriptyline as a positive control compound (fuinc 0.35–0.4). For blood partitioning, male Sprague Dawley rat, male Beagle dog and male CD-1 mouse blood was sourced from Harlan Sera-Lab Ltd, Loughborough, UK. Mixed sex human blood was obtained from in-house healthy donors. The hematocrit was measured using a Hettich Hematokrit 210 and calculated as the percentage of packed cell volume compared with the total volume of whole blood. EPZ-5676 (final test compound concentration 0.5 μM, final DMSO concentration 0.05%) was incubated separately with fresh heparinized whole blood, reference red blood cells and reference plasma for 60 min at 37 °C in triplicate. Following incubation, the whole blood cell samples were centrifuged for 5 min at 5000 × g at 4 °C. The spiked reference plasma was stored on ice during this period. The spiked reference red blood cells were freeze-thawed quickly three times to assist in lysing the red blood cells. Following centrifugation of the whole blood experimental sample, an aliquot was sampled from the plasma and red blood cell layers for analysis. As before, the red blood cell layer was freeze-thawed quickly three times to lyse the red blood cells. After protein precipitation and centrifugation, the supernatants for the experimental samples and reference samples were analysed by LC-MS/MS. Blood-to-plasma ratios were calculated as described previously [18]. Chlorthalidone was used as a positive control in this assay (rat B:P ratio of 73). For plasma stability, EPZ-5676 (1 μM) was incubated with pooled lots of human, Beagle dog, Sprague Dawley rat and CD-1 mouse plasma for 0, 15, 30, 60 and 120 min at 37 °C. Samples were quenched in methanol and analysed by LC-MS/ MS analysis. from the donor and receiver chambers at 120 min. Each determination was performed in duplicate. The co-dosed lucifer yellow flux was also measured for each monolayer to ensure cell monolayers remained intact during the incubation. The recovery of EPZ-5676 in donor and recipient wells postincubation was > 90% for all replicates. All samples were assayed by LC-MS/MS. Metabolite profiling and identification EPZ-5676 was incubated with liver microsomes of various species (mouse, rat, dog or human). In vitro metabolite profiling and identification were conducted after incubating EPZ-5676 (final concentration of 10 μM) with mouse, rat, dog or human liver microsomes (final protein concentration of 0.5 mg/ml) at 37 °C in 100 mM potassium phosphate buffer containing 2 mM Mg2+ in the presence of 2 mM NADPH and 2 mM uridine diphosphoglucuronic acid (UDPGA) (with the addition of 0.1 mg/ml alamethacin to human and rat microsomes). For all liver microsomal incubations, samples were taken at 0 and 20 min. All samples were quenched by using the acetonitrile/methanol solution and analysed using an LC-MS/MS Q-Trap system (AB Sciex, Framingham, MA). The major metabolites of EPZ-5676 in terms of the mass spectrometry response were identified by comparison of the LC-MS total ion chromatograms (TIC) of 0 min and 20 min samples in full scan mode using LightSight™ 2.0 software. The corresponding product ion tandem mass spectra of EPZ-5676 and its metabolites were obtained by using enhanced product ion (EPI) scans during positive ion electrospray. The possible chemical structures of the metabolites were deduced based on their MS1 and MS2 spectra. In addition, the hydroxylated t-butyl analog of EPZ-5676 was synthesized to aid metabolite structure elucidation. MDCK cell permeability assays Confluent monolayers of Madin-Darby canine kidney (MDCK) or MDCK-MDR1 (P-glycoprotein) cells, 7–14 days old, in Transwell® dual-chamber plates, with apical and basolateral compartments buffered at pH 7.4, were dosed on the apical side (A-to-B) or basolateral side (B-to-A) with EPZ5676 (10 μM) and incubated at 37 °C with 5% CO2 in a humidified incubator. Samples were taken Copyright © 2014 John Wiley & Sons, Ltd. Results In vivo pharmacokinetics The pharmacokinetics of EPZ-5676 was studied following i.v. bolus administration to mouse, rat and dog as well as following p.o. administration to mouse and rat. The time–concentration data are shown in Figure 1 and the parameters derived Biopharm. Drug Dispos. (2014) DOI: 10.1002/bdd A. BASAVAPATHRUNI ET AL. from non-compartmental analysis are displayed in Table 1. In mouse, rat and dog the plasma clearance was 77, 68 and 19 ml/min/kg, respectively, which equates to an extraction ratio of 0.86, 0.97 and 0.61, respectively (based on the total CL being entirely hepatic and using species-specific liver blood flows of 90, 70 and 31 ml/min/kg, respectively). Volumes of distribution at steady state were determined to be 1.58, 1.66 and 2.44 l/ kg in mouse, rat and dog, respectively. In physiological terms, this corresponds to about 2.2-, 2.4- and 3.5-fold greater than the total body water (0.7 l/kg), respectively, indicating partitioning into the peripheral tissue compartments. The kinetics following i.v. bolus administration in all three species showed bi-exponential decline, as evidenced by a terminal elimination half-life that was greater than the mean residence time (Table 1). In mouse and rat, following p.o. administration the exposure in terms of Cmax, AUC and oral bioavailability was low. Following i.v. administration in mouse, the parent excreted in urine equated to a CLr of 4.4 ml/min/kg. Plasma protein binding and blood:plasma partitioning The in vitro binding and partitioning data are shown in Table 2. The free fraction in plasma for EPZ-5676 did not show any marked species differences with values of 0.138, 0.272, 0.234 and 0.125 in mouse, rat, dog and human, respectively. The blood-to-plasma partitioning data across species did not suggest any significant binding of EPZ5676 to erythrocytes with values suggesting a fairly equal distribution between plasma and blood components. Based on these data, plasma clearance, rather than blood clearance, was used in all further data analysis. Figure 1. The preclinical pharmacokinetics of EPZ-5676 determined in mouse, rat and dog. Data are shown graphically as (A) concentration vs. time profile of mean ± SD (n = 3) plasma concentrations following i.v. bolus (5 mg/kg) administration to CD-1 mouse (formulated in 10% ethanol: 90% saline); (B) concentration vs. time profile of mean ± SD (n = 3) plasma concentrations following i.v. bolus (1 mg/kg formulated in 0.4% HPBCD in saline) administration to SD rat; (C) concentration vs. time profile of mean ± SD (n = 3) plasma concentrations following i.v. bolus (1 mg/kg formulated in 10% ethanol: 90% saline) administration to male Beagle dog Copyright © 2014 John Wiley & Sons, Ltd. In vitro metabolic stability A summary of the metabolic stability data across species is shown in Table 2. Representative plots of the depletion of EPZ-5676 over time in liver microsome incubations are shown in Figure 2. EPZ5676 did not show any instability in mouse, rat, dog and human plasma in vitro. Liver microsomal incubations supplemented with NADPH showed moderate turnover in mouse, rat, dog and human which, when scaled by the well-stirred venous Biopharm. Drug Dispos. (2014) DOI: 10.1002/bdd NONCLINICAL PK AND METABOLISM OF EPZ-5676, A DOT1L INHIBITOR Table 1. Pharmacokinetic parameters for EPZ-5676 in mouse, rat and dog after i.v. administration and in mouse and rat following p.o. administration. Expressed as mean ± SD where applicable. n.d., not determined CD-1 mouse SD rat Parameter i.v. bolus p.o. i.v. bolus p.o. n Dose (mg/kg) Cmax (μM) tmax (h) AUC0-t (μM.h) AUC0-inf (μM.h) t1/2 (h) MRT (h) CL (ml/min/kg) CLr (ml/min/kg) VDss (l/kg) F (%) 3/tpt 5 7.99 ± 1.90 3/tpt 20 0.0019 0.5 0.0014 n.d. n.d. n.d. 3 1 2.04 ± 0.23 3 10 0.0007a 0.25 n.d. n.d. n.d. n.d. 1.95 ± 0.28 1.96 ± 0.30 1.14 ± 0.35 0.35 ± 0.06 76.7 ± 11.5 4.4 1.58 ± 0.23 0.43 ± 0.03 0.44 ± 0.03 3.73 ± 1.03 0.41 ± 0.10 67.8 ± 5.3 n.d. 1.66 ± 0.42 n.d. Beagle dog i.v. bolus 3 1 5.06 ± 0.60 1.55 ± 0.16 1.60 ± 0.15 13.6 ± 2.8 2.17 ± 0.89 18.7 ± 1.7 n.d. 2.44 ± 1.11 n.d. a Corresponds to LLOQ of bioanalytical assay. Table 2. Liver microsome stability, hepatocyte stability, scaled hepatic CL and blood and plasma binding across species for EPZ-5676 Species Mouse Rat Dog Human Scaled hepatic CL from liver microsomes with no binding correction (ml/min/kg) Scaled hepatic CL from liver microsomes with fup correction (ml/min/kg) Scaled hepatic CL from hepatocytes with no binding correction (ml/min/kg) Fraction unbound in plasma (fup) Fraction unbound in liver microsome incubation (fuinc) Blood: plasma ratio Half-life in plasma in vitro (min) 78 43 26 0.138 0.797 2.15 > 120 45 23 7 0.272 0.771 0.77 > 120 20 9 21 0.234 0.717 1.16 > 120 17 8 <3 0.125 0.772 0.65 > 120 equilibration liver model (with no correction for binding), gave hepatic CL values of 78, 45, 20 and 17 ml/min/kg indicating moderate to high hepatic extraction in mouse, rat, dog and human, respectively. Incorporating the fraction unbound in plasma into the microsomal scaling gave hepatic CL values of 43, 23, 9 and 8 ml/min/kg in mouse, rat, dog and human, respectively. Incubational binding to liver microsomes across species was shown to be low (fu > 0.7 in all cases) and so was not considered a major contributing factor in the in vitro–in vivo extrapolation (IVIVE) for either liver microsomes or hepatocytes since it is largely driven by non-specific membrane partitioning and physicochemical properties. In liver microsomal preparations supplemented with UDPGA and alamethacin, no turnover was observed indicating glucuronidation is not a primary metabolic pathway for EPZ-5676 (data not shown). In the hepatocyte suspensions, the turnover of EPZ-5676 was very low giving rise to Copyright © 2014 John Wiley & Sons, Ltd. low CL estimates in all species tested, with the exception of dog where a hepatic CL value of 21 ml/min/ kg was observed. Permeability in MDCK cell monolayers The permeability of EPZ-5676 in mock and MDR1-transfected MDCK cell monolayers is shown in Table 3. EPZ-5676 showed low apicalto-basolateral permeability in both cell lines with mean Papp values of less than 0.1 × 10-6 cm/s estimated over a 120 min incubation. The relative efflux ratio between the transfected and native cell lines suggests EPZ-5676 was not a substrate for P-gp. However, both cell lines indicate an efflux ratio of approximately 3, suggesting the action of a native transporter protein in the basolateral-to-apical efflux of EPZ-5676. Similar observations were made in the transport assays using the Caco-2 cell line (data not shown). This is currently being investigated further. Biopharm. Drug Dispos. (2014) DOI: 10.1002/bdd A. BASAVAPATHRUNI ET AL. Figure 2. Representative plots showing the depletion of EPZ-5676 in liver microsomes supplemented with NADPH. Parent depletion expressed as natural logarithm of the percent remaining as peak area ratio (parent/internal standard). (A) mouse, (B) rat, (C) 2 dog and (D) human. The r for all regressions was > 0.95 Table 3. Permeability of EPZ-5676 across MDCK cell monolayers over 2 h Cell line MDCK - mock MDCK – MDR1 transfected -6 Direction Mean Papp (× 10 cm/s) Apical-to-basolateral Basolateral-to-apical Apical-to-basolateral Basolateral-to-apical 0.09 0.30 < 0.06 0.22 Structural elucidation of the major metabolites of EPZ-5676 by LC-MS and LC-MS/MS The metabolism of EPZ-5676 was studied in vitro in liver microsomes supplemented with NADPH and UDPGA, with several metabolites detected in mouse, rat, dog and human. LC-MS and LC-MS/ MS were used for identification of EPZ-5676 and its metabolites. A representative HPLC-MS chromatogram of the metabolite profile following a 20 min incubation is shown in Figure 3. The molecular ions and characteristic fragment ions are illustrated in Figures 4–7. A summary of the metabolites identified is presented in Table 4 and the proposed metabolic pathway is shown in Figure 8. EPZ-5676. The protonated molecular ion of EPZ5676 was m/z 563. The proposed fragmentation Copyright © 2014 John Wiley & Sons, Ltd. Efflux ratio 3.3 Relative efflux ratio <2 > 3.8 pathway is shown in Figure 4. Loss of the adenine ring gave m/z 428, with m/z 136 corresponding to the protonated adenine ring itself. Loss of the adenosine moiety gave m/z 326, due to the neutral loss of both the ribose and adenine ring systems. Cleavage of the N-cyclobutyl bond gave rise to m/ z 255 corresponding to the protonated t-butylbenzimidazole-cyclobutyl portion of EPZ-5676. Metabolites showed similar fragmentation pathways, which allowed the elucidation and assignment of metabolite structures. M1. The protonated molecular ion of M1 was m/z 579, indicating a mass shift of +16 Da and a mono-hydroxylation of EPZ-5676. The proposed fragmentation pathway is shown in Figure 5. Comparison of the MS2 data of M1 Biopharm. Drug Dispos. (2014) DOI: 10.1002/bdd NONCLINICAL PK AND METABOLISM OF EPZ-5676, A DOT1L INHIBITOR Figure 3. Representative HPLC-MS chromatograms for T0min and T20min incubations of EPZ-5676 in liver microsomes supplemented with NADPH and UDPGA. This plot corresponds to a mouse liver microsome experiment with that from the parent compound suggested the mono-hydroxylation occurred on the t-buty l-benzimidazole-cyclobutyl portion of the molecule. This was supported by the fragment ions from M1 with m/z 444, 342, 330 and 271 all retaining a +16 Da mass shift with corresponding ions from EPZ-5676 (m/z 428, 326, 314 and 255). The fragment ion m/z 136, corresponding to the adenine ring, was present in MS2 spectra for both parent and M1. The exact site of hydroxylation was confirmed on the t-butyl group with a synthesized authentic reference standard, which showed an identical retention time and MS fragmentation pattern to M1. M3. The protonated molecular ion of M3 was m/z 579, indicating a mass shift of +16 Da and a mono-hydroxylation of EPZ-5676. The MS2 data for M3 gave fragment ions of m/z 444, 342 and 271, and was differentiated structurally from M1 based on chromatographic separation. M4. The protonated molecular ion of M4 was m/z 521, indicating a mass shift of 42 Da and dealkylation of the N-isopropyl group of EPZ-5676. The proposed fragmentation pathway is shown in Figure 6. Comparing the MS2 data with that of parent revealed the fragment ions m/z 255 and 136 were identical in both Copyright © 2014 John Wiley & Sons, Ltd. species, while the product ions m/z 386, 368, 350 and 284 supported N-dealkylation of the isopropyl group. M5. The protonated molecular ion of M5 was m/z 579, indicating a mass shift of +16 Da and a mono-hydroxylation of EPZ-5676. The MS2 data for M5 gave fragment ions of m/z 444, 342 and 271, and as such could not be differentiated structurally from M3. M6. The protonated molecular ion of M6 was m/z 579, indicating a mass shift of +16 Da and based on retention time was tentatively assigned as an N-oxidation product of EPZ-5676. The proposed fragmentation pathway is shown in Figure 7. The MS2 product ions of m/z 428, 326 and 255 were characteristic of the benzimidazole, cyclobutyl and ribose moieties of the parent molecule suggesting oxidation of the adenine ring. The rationale for the N-oxide assignment is further described in Discussion. Discussion EPZ-5676 is a novel DOT1L inhibitor and the first member of the novel HMTi class to enter clinical development as a potential therapeutic agent in Biopharm. Drug Dispos. (2014) DOI: 10.1002/bdd A. BASAVAPATHRUNI ET AL. Figure 4. LC-MS chromatogram, MS1 and MS2 spectra (A) with proposed fragmentation pathways of EPZ-5676 (B) MLL-rearranged leukemia. The discovery of EPZ-5676 was facilitated by a structure-guided medicinal chemistry approach [10] and has shown superior efficacy in preclinical models of MLL-rearranged leukemia [11]. The aims of this work were to characterize the pharmacokinetics following i.v. and p.o. administration in mouse, rat and dog, to assess the cross-species in vitro–in vivo correlation to gain insight into the primary elimination pathways involved in the clearance of EPZ-5676, and to determine the major metabolic pathways. The in vivo time–concentration profiles in mouse, rat and dog following i.v. bolus administration showed biexponential kinetics that was more apparent as the body size of the species increased. Copyright © 2014 John Wiley & Sons, Ltd. This resulted in terminal half-lives increasing from 1.1 h in mouse, 3.7 h in rat and 13.6 h in dog. In addition, terminal t1/2 was longer than mean residence time (MRT) (3–9 fold) further supporting multi-exponential kinetics in the animal species [19]. As for many drugs that exhibit multiphasic concentration vs time profiles, the MRT will be a better indicator than t1/2 of the potential dosing frequency needed and expected accumulation ratio that will occur with repeated administration. The CL in all species was moderate to high with estimated hepatic extraction ratios of 0.80, 0.97 and 0.61 in mouse (accounting for the measured renal component), rat and dog, respectively. Expressing CL in its unbound or blood form did not change the interpretation of the cross-species Biopharm. Drug Dispos. (2014) DOI: 10.1002/bdd NONCLINICAL PK AND METABOLISM OF EPZ-5676, A DOT1L INHIBITOR Figure 5. MS2 spectra of M1 (m/z 579) and EPZ-5676 (m/z 563) (A) with proposed fragmentation (B) differences, since there was reasonable agreement across species in the plasma-free fraction and with blood partitioning values around unity. The volume of distribution at steady state was consistent across species with values 2–3 fold greater than the total body water indicating partitioning into peripheral tissues. The unbound volume of distribution at steady state (VDss) was also fairly consistent across species at 11.4, 6.1 and 10.4 l/kg in mouse, rat and dog, respectively. EPZ-5676 showed negligible oral bioavailability in mouse and rat, which is in line with the physicochemical property space that is generally regarded as necessary for favorable gastrointestinal absorption, e.g. PSA < 120 Å2, MW < 500 Da [20]. EPZ-5676 has a calculated logP of 3.26, a PSA of 144 Å2 and a molecular weight of 563 Da. The oral absorption Copyright © 2014 John Wiley & Sons, Ltd. is permeability-limited based on the low passive permeation observed in MDCK cell monolayers. Additionally the data suggest that low intrinsic permeation is the key driver rather than an active efflux process as there was no indication of EPZ5676 as a P-gp substrate. The oral exposure may also be perturbed by moderate-to-high first pass extraction in rodents. Based on these data, an i.v. dosing paradigm was pursued as the clinical route of administration. The scaled clearance from liver microsomes showed excellent agreement with in vivo clearances in the preclinical species, supporting perfusion-limited CL and hepatic oxidative metabolism as the primary elimination pathway. Additional in vitro metabolism studies confirmed no evidence of glucuronidation in all species tested and no instability in blood plasma. Biopharm. Drug Dispos. (2014) DOI: 10.1002/bdd A. BASAVAPATHRUNI ET AL. Figure 6. MS2 spectra of M4 (m/z 521) and EPZ-5676 (m/z 563) (A) with proposed fragmentation (B) Moreover, low renal clearance was observed in mouse. The estimated passive renal filtration (expressed as GFR*fu) in mouse was ca. 2 ml/min/kg for EPZ-5676 which is slightly lower than the observed CLr of 4.4 ml/min/kg. This suggests largely a passive glomerular filtration mechanism with perhaps a marginal contribution from active tubular secretion in mouse kidney. Notwithstanding, renal elimination of parent is a quantitatively minor contribution to the overall elimination of EPZ-5676, representing ca. 7% of mouse renal blood flow. Scaled clearance from liver microsomes supplemented with NADPH provided good agreement with in vivo clearance across all three preclinical species. Even in the case of incorporating unbound fraction in plasma into the wellCopyright © 2014 John Wiley & Sons, Ltd. stirred venous equilibration model, the CL estimates remained within 2–3 fold of the measured clearance. This case study highlights one of the current challenges and limitations in IVIVE in terms of whether to incorporate the plasma-free fraction when the level of protein binding is low to moderate and introduces a fold change in CL coincident with the current practical limit in predictive accuracy for IVIVE of 2–3 fold. It is a common observation that liver microsomes have a tendency to overpredict CL especially for compounds with low passive membrane permeability, although that was not apparent for EPZ-5676. However, low scaled hepatocyte CL values were obtained for EPZ-5676 in mouse, rat and human (CLint < 4 μl/min/million cells). Dog Biopharm. Drug Dispos. (2014) DOI: 10.1002/bdd NONCLINICAL PK AND METABOLISM OF EPZ-5676, A DOT1L INHIBITOR Figure 7. MS2 spectra of M6 (m/z 579) and EPZ-5676 (m/z 563) (A) with proposed fragmentation (B) Table 4. Summary of metabolites of EPZ-5676 generated in liver microsomes supplemented with NADPH and UDPGA in various species Abundance based on UV spectra (%)* Metabolite Parent M1 M3 M4 M5 M6 Mass shift (Da) m/z Retention time (min) 0 +16 +16 42 +16 +16 563.2 579.3 579.3 521.3 579.3 579.3 18.5 16.3 17.2 17.4 17.8 18.0 Mouse Rat Human 25.4 4.5 6.7 59.4 11.3 59 2.6 3.5 3.8 10.3 9.3 *Not possible accurately to quantify the metabolites in dog by UV due to low signal. was a clear outlier in terms of scaled hepatocyte clearance and this may relate to a hepatic uptake process well represented in dog. This is supported by the slightly higher VDss observed in dog which would correspond to greater tissue permeation Copyright © 2014 John Wiley & Sons, Ltd. and uptake. Interestingly, with the exception of dog, the scaled hepatocyte data gave rise to much lower values between 3- and 10-fold lower than the observed CL, suggesting that permeation or hepatocyte uptake was rate limiting. This has Biopharm. Drug Dispos. (2014) DOI: 10.1002/bdd A. BASAVAPATHRUNI ET AL. Figure 8. The proposed major metabolic pathways of EPZ-5676 in mouse, rat, dog and human liver microsomes (supplemented with NADPH and UDPGA) been demonstrated for other compounds showing a similar disparity between the liver microsome and hepatocyte clearance [21]. Liver microsomes were selected for metabolite identification and profiling, in light of the superior cross-species IVIVE and much lower turnover observed in hepatocytes. In liver microsomes supplemented with NADPH and UDPGA, several oxidative metabolites were observed. Metabolite M1 was confirmed to be the product of hydroxylation on the t-butyl group based on the identical LC-MS/MS characteristics of a synthesized authentic standard. Metabolite M1 was observed in all species including human. Metabolites M3 and M5 were distinct mono-hydroxylations on the benzimidazole portion of the molecule. Due to the poor MS fragmentation of the cyclobutylbenzimidazole moiety, LC-MS/MS alone was not sufficient to elucidate the exact position of these two hydroxylations. Metabolite M3 was only observed in rat, whilst M5 was present in all preclinical species as well as human. Metabolite Copyright © 2014 John Wiley & Sons, Ltd. M4, N-dealkylation and loss of the isopropyl group, was observed in all species tested whilst M6, the N-oxidation of the adenine ring, was only observed in rat. The most compelling evidence for the assignment of M6 is based on previous work on the oxidative metabolism of adenine analogs. Lam and colleagues have demonstrated that 9-substituted adenine analogs including 9-benz yl adenine predominantly form the 1-N-oxide in rodent microsomes whilst adenine itself and smaller analogs such as 9-methyl adenine do not [22]. In addition, none of the adenine analogs tested underwent N-hydroxylation at the 6-amino group [22]. No glucuronides of EPZ-5676 or its hydroxylated metabolites were detected and no metabolites unique to human were present in this in vitro metabolism study. Other groups have recently reported on the in vitro metabolic stability of similar nucleoside-analog inhibitors of DOT1L [23,24]. The replacement of the ribose moiety with carbocycles, such as cyclopentane, and to a lesser extent cyclopentene, was advocated based on in vitro Biopharm. Drug Dispos. (2014) DOI: 10.1002/bdd NONCLINICAL PK AND METABOLISM OF EPZ-5676, A DOT1L INHIBITOR stability in human plasma and liver microsomes. Differences in human liver microsome turnover were observed between these two carbocyclic analogs with the implication that the 5-membered ring system was a metabolic liability. Our data do not support the ribose moiety as being a major metabolic soft-spot but rather suggest that P450mediated metabolism elsewhere on the molecule is the major metabolic pathway for the DOT1L nucleoside analog chemotype. Conclusion EPZ-5676 showed biexponential kinetics following i.v. administration, giving rise to a terminal t1/2 of 1.1, 3.7 and 13.6 h in mouse, rat and dog, respectively. Steady state VD was 2–3-fold greater than total body water with a high clearance in rodent and moderate clearance in dog. EPZ-5676 exhibited a low oral bioavailability in rodent. In vitro scaling of liver microsome clearance data showed good agreement with the in vivo clearance across species indicating P450-mediated metabolism as a primary elimination pathway. Moreover, low renal clearance was observed in mouse mediated largely by passive glomerular filtration. Hepatocyte clearance suggested permeation- or hepatic uptakelimitations. The metabolic pathways for EPZ-5676 across species included three monohydroxylated metabolites (M1, M3 and M5), one N-dealkylated product (M4) as well as an N-oxide (M6). EPZ-5676 is a first-in-class DOT1L inhibitor and is currently under clinical investigation for MLL-rearranged leukemias. Further work is underway at present to characterize the metabolism and disposition of EPZ-5676. Conflict of Interest The authors have declared that there is no conflict of interest. All authors are employees of, and/or hold equity in, Epizyme, Inc. References 1. Portela A, Esteller M. Epigenetic modifications and human disease. Nature Biotechnol 2010; 28: 1057–1068. Copyright © 2014 John Wiley & Sons, Ltd. 2. Tamai H, Inokuchi K. 11q23/MLL acute leukemia: update of clinical aspects. J Clin Exp Hematopathol 2010; 50: 91–98. 3. Ayton PM, Chen EH, Cleary ML. Binding to nonmethylated CpG DNA is essential for target recognition, transactivation, and myeloid transformation by an MLL oncoprotein. Mol Cell Biol 2004; 24: 10470–10478. 4. Milne TA, Briggs SD, Brock HW, et al. MLL targets SET domain methyltransferase activity to Hox gene promoters. Mol Cell 2002; 10: 1107–1117. 5. Nakamura T, Mori T, Tada S, et al. ALL-1 is a histone methyltransferase that assembles a supercomplex of proteins involved in transcriptional regulation. Mol Cell 2002; 10: 1119–1128. 6. Slany RK, Lavau C, Cleary ML. The oncogenic capacity of HRX-ENL requires the transcriptional transactivation activity of ENL and the DNA binding motifs of HRX. Mol Cell Biol 1998; 18: 122–129. 7. Zeleznik-Le NJ, Harden AM, Rowley JD. 11q23 translocations split the ‘AT-hook’ cruciform DNA-binding region and the transcriptional repression domain from the activation domain of the mixed-lineage leukemia (MLL) gene. Proc Natl Acad Sci U S A 1994; 91: 10610–10614. 8. Biswas D, Milne TA, Basrur V, et al. Function of leukemogenic mixed lineage leukemia 1 (MLL) fusion proteins through distinct partner protein complexes. Proc Natl Acad Sci U S A 2011; 108: 15751–15756, S/1–S/7. 9. Daigle SR, Olhava EJ, Therkelsen CA, et al. Selective killing of mixed lineage leukemia cells by a potent small-molecule DOT1L inhibitor. Cancer Cell 2011; 20: 53–65. 10. Basavapathruni A, Jin L, Daigle SR, et al. Conformational adaptation drives potent, selective and durable inhibition of the human protein methyltransferase DOT1L. Chem Biol Drug Design 2012; 80: 971–980. 11. Daigle SR, Olhava EJ, Therkelsen CA, et al. Potent inhibition of DOT1L as treatment for MLL-fusion leukemia. Blood 2013; 122(6): 1017–1025. 12. Pang KS, Rowland M. Hepatic clearance of drugs. I. Theoretical considerations of a ‘well-stirred’ model and a ‘parallel tube’ model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm 1977; 5: 625–653. 13. Obach RS. Prediction of human clearance of twenty-nine drugs from hepatic microsomal intrinsic clearance data: an examination of in vitro halflife approach and nonspecific binding to microsomes. Drug Metab Dispos 1999; 27: 1350–1359. 14. Houston JB. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 1994; 47: 1469–1479. 15. Barter ZE, Bayliss MK, Beaune PH, et al. Scaling factors for the extrapolation of in vivo metabolic drug clearance from in vitro data: reaching a consensus on values of human microsomal protein Biopharm. Drug Dispos. (2014) DOI: 10.1002/bdd A. BASAVAPATHRUNI ET AL. 16. 17. 18. 19. 20. and hepatocellularity per gram of liver. Curr Drug Metab 2007; 8: 33–45. Davies B, Morris T. Physiological parameters in laboratory animals and humans. Pharm Res 1993; 10: 1093–1095. Ring BJ, Chien JY, Adkison KK, et al. PhRMA CPCDC Initiative on Predictive Models of Human Pharmacokinetics, Part 3: Comparative assessment of prediction methods of human clearance. J Pharm Sci 2011; 100: 4090–4110. Hinderling PH. Red blood cells: a neglected compartment in pharmacokinetics and pharmacodynamics. Pharmacol Rev 1997; 49: 279–295. Sahin S, Benet LZ. The operational multiple dosing half-life: a key to defining drug accumulation in patients and to designing extended release dosage forms. Pharm Res 2008; 25: 2869–2877. van de Waterbeemd H. Physicochemical Approaches to Drug Absorption. In Drug Bioavailability: Copyright © 2014 John Wiley & Sons, Ltd. 21. 22. 23. 24. Estimation of Solubility, Permeability, Absorption and Bioavailability, van de Waterbeemd H, Testa B (eds). Wiley-VCH Verlag GmbH & Co. KGaA: Weinheim, Germany, 2009; 40: 71–99. doi: 10.1002/ 9783527623860.ch5. Di L, Keefer C, Scott DO, et al. Mechanistic insights from comparing intrinsic clearance values between human liver microsomes and hepatocytes to guide drug design. Eur J Med Chem 2012; 57: 441–448. Lam SP, Devinsky F, Gorrod JW. Biological N-ox idation of adenine and 9-alkyl derivatives. Eur J Drug Metab Pharmacokinet 1987; 12: 239–243. Deng L, Zhang L, Yao Y, et al. Synthesis, activity and metabolic stability of non-ribose containing inhibitors of histone methyltransferase DOT1L. Med Chem Comm 2013; 4: 822–826. Anglin JL, Song Y. A medicinal chemistry perspective for targeting histone H3 lysine79 methyltransferase DOT1L. J Med Chem 2013; 56(22): 8972–8983. Biopharm. Drug Dispos. (2014) DOI: 10.1002/bdd